{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:22:29Z","timestamp":1777904549260,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Plus"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.athplu.2026.01.003","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T06:32:40Z","timestamp":1768717960000},"page":"28-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Statin treatment in routine clinical practice: Insights from the STATRIP physician survey"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-4629","authenticated-orcid":false,"given":"Panagiota","family":"Anyfanti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Antza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Poulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Konstantaros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makrina","family":"Savvoulidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Styliadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3755-8097","authenticated-orcid":false,"given":"Vasilios","family":"Kotsis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.athplu.2026.01.003_bib1","series-title":"Cardiovascular diseases (CVDs). [Internet]","year":"2021"},{"key":"10.1016\/j.athplu.2026.01.003_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa2415879","article-title":"Global effect of cardiovascular risk factors on lifetime estimates","volume":"393","author":"Magnussen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.athplu.2026.01.003_bib3","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1080\/14656566.2019.1604687","article-title":"Current pharmacotherapeutic options for primary dyslipidemia in adults","volume":"20","author":"Cicero","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.athplu.2026.01.003_bib4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40265-024-02046-z","article-title":"Therapeutic potential of lipoprotein(a) inhibitors","volume":"84","author":"Nicholls","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.athplu.2026.01.003_bib5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2026.01.003_bib6","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2026.01.003_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14020493","article-title":"Therapeutic inertia in dyslipidemia management for secondary cardiovascular prevention: results from the Italian ITACARE-P network","volume":"14","author":"Faggiano","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.athplu.2026.01.003_bib8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","article-title":"Clinical inertia","volume":"135","author":"Phillips","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.athplu.2026.01.003_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.athplu.2024.01.004","article-title":"Executive summary of the Hellenic atherosclerosis society guidelines for the diagnosis and treatment of dyslipidemias - 2023","volume":"55","author":"Katsiki","year":"2024","journal-title":"Atheroscler Plus"},{"key":"10.1016\/j.athplu.2026.01.003_bib10","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2026.01.003_bib11","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract","volume":"39","author":"Mach","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2026.01.003_bib12","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","article-title":"Adverse events associated with unblinded, but not with blinded, statin therapy in the anglo-scandinavian cardiac outcomes trial-lipid-lowering arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.athplu.2026.01.003_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2022.12567","article-title":"Trends in lipid concentrations and lipid control among US adults, 2007-2018","volume":"328","author":"Aggarwal","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.athplu.2026.01.003_bib14","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.mayocp.2025.01.018","article-title":"Impact of lipid-lowering combination therapy with statins and ezetimibe vs Statin monotherapy on the reduction of cardiovascular outcomes: a meta-analysis","volume":"100","author":"Banach","year":"2025","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.athplu.2026.01.003_bib15","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf357","article-title":"Statin use for primary prevention of cardiovascular disease among apparently healthy adults","author":"Halili","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.athplu.2026.01.003_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejim.2023.10.013","article-title":"Residual cardiovascular risk: when should we treat it?","volume":"120","author":"Gomez-Delgado","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.athplu.2026.01.003_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0280432","article-title":"Physicians and pharmacists' clinical knowledge of statin therapy and monitoring parameters, and the barriers to guideline implementation in clinical practice","volume":"18","author":"Al-Ashwal","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.athplu.2026.01.003_bib18","doi-asserted-by":"crossref","DOI":"10.5114\/aoms\/196806","article-title":"Facts and myths about use and effect of statins in patients with dyslipidaemia - a survey of physicians","author":"Hendzel","year":"2025","journal-title":"Arch Med Sci"}],"container-title":["Atherosclerosis Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089526000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089526000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:27:31Z","timestamp":1777638451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667089526000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":18,"alternative-id":["S2667089526000039"],"URL":"https:\/\/doi.org\/10.1016\/j.athplu.2026.01.003","relation":{},"ISSN":["2667-0895"],"issn-type":[{"value":"2667-0895","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin treatment in routine clinical practice: Insights from the STATRIP physician survey","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athplu.2026.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}